Xenogeneic iso-skin graft and mixed lymphocyte reaction studies using HLA-DP transgenic mice. NLM AIDSLINE Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Xenogeneic iso-skin graft and mixed lymphocyte reaction studies using HLA-DP transgenic mice.

Transpl Immunol. 1996 Sep;4(3):220-6. Unique Identifier : AIDSLINE MED/97048622
Hagihara M; Shimura T; Takebe K; Munkhbat B; Sato T; Tsuchida F; Sato K; Tsuji K; Department of Transplantation Immunology, Tokai University School; of Medicine, Kanagawa, Japan.


Abstract: To elucidate the cellular responses against xeno-MHC antigens, in vitro mixed lymphocyte culture (MLC) and in vivo skin grafting (SG) studies were conducted using HLA-DP transgenic mice (B6-DP mice). Xenogenic iso-(B6-DP to B6 mice) MLC showed positive but much lower responses compared to allo-MLC responses. Nevertheless, B6-DP skin grafts were rejected in a similar time course as allo-skin grafts. To examine mechanisms underlining skin graft rejection, both in vitro cytotoxic lymphocyte (CTL) responses and delayed-type hypersensitivity (DTH) reactions were tested. The studies showed that DTH but not CTL reactions were involved for the graft rejection. SG was again conducted after the administration of anti-CD4 and/or CD8 monoclonal antibody (mAb). Mice treated with both CD4 and CD8 mAb accepted B6-DP SG for as long as up to 60 days and those treated with either CD4 or CD8 mAb alone rejected skin grafts on its own most of the time (75% in anti-CD4 mAb treated mice, 88.9% in anti-CD8 mAb treated mice), which suggests that the strict T cell restrictions for xeno-DP antigens do not exist. Even in these finally rejected cases, longer median survival time and final rejection time were observed, and in the other mice (25% in anti-CD4 mAb treated, and 11.1% in anti-CD8 mAb treated mice), graft acceptance was found. Therefore, it was suggested that the immunological reactions leading to the graft rejection occurs most efficiently when both T cell subsets are present. The above results indicate that xenogeneic HLA-DP antigens could act as significant transplantation antigens equivalent to alloantigens despite their lower stimulative activity in vitro, and also support the interpretation that DP antigens act like a minor histocompatibility antigen beyond the difference of species. Monomorphic anti-HLA class II antibodies were detected in recipients' sera as early as 2 weeks and even at 6 months, indicating that xeno-MHC antigens are prone to be memorized to B cells. It was concluded that HLA transgenic mice are useful for the investigation of cellular responses across xeno-MHC barriers.
Keywords: Animal Antibodies/ANALYSIS CD4-CD8 Ratio Histocompatibility Antigens Class II/IMMUNOLOGY Hypersensitivity, Delayed/IMMUNOLOGY HLA-DP Antigens *Lymphocyte Culture Test, Mixed Lymphocyte Transformation Lymphocytes/IMMUNOLOGY Mice Mice, Inbred BALB C Mice, Inbred C3H Mice, Transgenic/*IMMUNOLOGY Skin/IMMUNOLOGY Skin Transplantation/*IMMUNOLOGY/PATHOLOGY Spleen/CYTOLOGY T-Lymphocytes, Cytotoxic/IMMUNOLOGY Transplantation, Heterologous Transplantation, Isogeneic JOURNAL ARTICLEKWDanimalantibodies/analysiscd4-cd8ratiohistocompatibilityantigensclassii/immunologyhypersensitivity,delayed/immunologyhla-dpantigensKWDlymphocyteculturetest,mixedlymphocytetransformationlymphocytes/immunologymicemice,inbredbalbcmice,inbredc3hmice,transgenic/KWDimmunologyskin/immunologyskintransplantation/KWDimmunology/pathologyspleen/cytologyt-lymphocytes,cytotoxic/immunologytransplantation,heterologoustransplantation,isogeneicjournalarticle
970228
M9721933

Copyright © 1997 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .